World Workshop on Oral Medicine VII: Immunobiologics for salivary gland disease in Sjogren's syndrome: A systematic review

被引:18
作者
Gueiros, Luiz A. [1 ]
France, Katherine [2 ]
Posey, Rachael [3 ]
Mays, Jacqueline W. [4 ]
Carey, Barbara [5 ]
Sollecito, Thomas P. [2 ]
Setterfield, Jane [5 ]
Woo, Sook Bin [6 ]
Culton, Donna [7 ]
Payne, Aimee S. [8 ]
Lodi, Giovanni [9 ]
Greenberg, Martin S. [2 ]
De Rossi, Scott [10 ]
机构
[1] Univ Fed Pernambuco, Dept Clin & Prevent Dent, Oral Med Unit, Recife, PE, Brazil
[2] Univ Penn, Sch Dent Med, Dept Oral Med, Philadelphia, PA 19104 USA
[3] North Carolina State Univ, William Rand Kenan Jr Lib Vet Med, Raleigh, NC 27695 USA
[4] Natl Inst Dent & Craniofacial Res, Oral Immunobiol Unit, NIH, Bethesda, MD USA
[5] Guys & St Thomas NHS Fdn Trust, Dept Oral Med, London, England
[6] Harvard Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA USA
[7] Univ N Carolina, Dept Dermatol, Chapel Hill, NC 27515 USA
[8] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA
[9] Univ Milan, Dipartimento Sci Biomed Chirurg & Odontoiatr, Oral Med Unit, Milan, Italy
[10] Univ N Carolina, Sch Dent, Chapel Hill, NC 27515 USA
关键词
biologic agents; salivary flow; Sjogren's syndrome; xerostomia; DOUBLE-BLIND; OPEN-LABEL; CLASSIFICATION CRITERIA; RITUXIMAB TREATMENT; TREATMENT GUIDELINES; AMERICAN-COLLEGE; CONTROLLED-TRIAL; BIOLOGIC AGENTS; DATA-DRIVEN; CONSENSUS;
D O I
10.1111/odi.13062
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Objective This systematic review evaluated the efficacy of immunobiologics for the management of oral disease in Sjogren's syndrome (SS). Materials and Methods MEDLINEA (R), Embase, Scopus, and the Cochrane Library were searched for evidence on the use of immunobiologics for management of glandular disease in SS. Primary outcomes were xerostomia and salivary gland dysfunction, assessed via visual analogue scales, disease-specific scales for SS, measurement of salivary flow, ultrasound data, and quality of life measures. Results Seventeen studies (11 randomized controlled trials and 6 observational studies) met inclusion criteria. Rituximab showed efficacy in improving salivary gland function but not xerostomia. Abatacept showed promise in improving both xerostomia and salivary flow. Belimumab exhibited long-term improvement of salivary flow and subjective measures. The novel agent CFZ533 improved both disease activity and patient-reported indexes. Conclusions There is strong evidence pointing to the efficacy of rituximab in the management of oral disease in SS. Future controlled trials may elucidate the efficacy of belimumab and abatacept. The new drug CFZ533 is a promising alternative for the management of SS and its salivary gland involvement. In considering these agents, the promise of efficacy must be balanced against the harmful effects associated with biologic agents.
引用
收藏
页码:102 / 110
页数:9
相关论文
共 46 条
[1]   Evaluation of Histologic, Serologic, and Clinical Changes in Response to Abatacept Treatment of Primary Sjogren's Syndrome: A Pilot Study [J].
Adler, Sabine ;
Koerner, Meike ;
Foerger, Frauke ;
Huscher, Doerte ;
Caversaccio, Marco-Domenico ;
Villiger, Peter M. .
ARTHRITIS CARE & RESEARCH, 2013, 65 (11) :1862-1868
[2]   Interventions for dry mouth and hyposalivation in Sjogren's syndrome: A systematic review and meta-analysis [J].
Al Hamad, Arwa ;
Lodi, Giovanni ;
Porter, Stephen ;
Fedele, Stefano ;
Mercadante, Valeria .
ORAL DISEASES, 2019, 25 (04) :1027-1047
[3]   Lymphoma and Lymphomagenesis in Primary Sjogren's Syndrome [J].
Alunno, Alessia ;
Leone, Maria Comasia ;
Giacomelli, Roberto ;
Gerli, Roberto ;
Carubbi, Francesco .
FRONTIERS IN MEDICINE, 2018, 5
[4]  
[Anonymous], 2019, NCI Dictionary of Cancer Terms
[5]   Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjogren's Syndrome [J].
Bowman, Simon J. ;
Everett, Colin C. ;
O'Dwyer, John L. ;
Emery, Paul ;
Pitzalis, Costantino ;
Ng, Wan-Fai ;
Pease, Colin T. ;
Price, Elizabeth J. ;
Sutcliffe, Nurhan ;
Gendi, Nagui S. T. ;
Hall, Frances C. ;
Ruddock, Sharon P. ;
Fernandez, Catherine ;
Reynolds, Catherine ;
Hulme, Claire T. ;
Davies, Kevin A. ;
Edwards, Christopher J. ;
Lanyon, Peter C. ;
Moots, Robert J. ;
Roussou, Euthalia ;
Giles, Ian P. ;
Sharples, Linda D. ;
Bombardieri, Michele .
ARTHRITIS & RHEUMATOLOGY, 2017, 69 (07) :1440-1450
[6]   Treatment Guidelines for Rheumatologic Manifestations of Sjogren's Syndrome: Use of Biologic Agents, Management of Fatigue, and Inflammatory Musculoskeletal Pain [J].
Carsons, Steven E. ;
Vivino, Frederick B. ;
Parke, Ann ;
Carteron, Nancy ;
Sankar, Vidya ;
Brasington, Richard ;
Brennan, Michael T. ;
Ehlers, William ;
Fox, Robert ;
Scofield, Hal ;
Hammitt, Katherine M. ;
Birnbaum, Julius ;
Kassan, Stuart ;
Mandel, Steven .
ARTHRITIS CARE & RESEARCH, 2017, 69 (04) :517-527
[7]   Efficacy and safety of rituximab treatment in early primary Sjogren's syndrome: a prospective, multi-center, follow-up study [J].
Carubbi, Francesco ;
Cipriani, Paola ;
Marrelli, Alessandra ;
Di Benedetto, Paola ;
Ruscitti, Piero ;
Berardicurti, Onorina ;
Pantano, Ilenia ;
Liakouli, Vasiliki ;
Alvaro, Saverio ;
Alunno, Alessia ;
Manzo, Antonio ;
Ciccia, Francesco ;
Gerli, Roberto ;
Triolo, Giovanni ;
Giacomelli, Roberto .
ARTHRITIS RESEARCH & THERAPY, 2013, 15 (05)
[8]   Randomized, controlled trials, observational studies, and the hierarchy of research designs. [J].
Concato, J ;
Shah, N ;
Horwitz, RI .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (25) :1887-1892
[9]   Severe Health-Related Quality of Life Impairment in Active Primary Sjogren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial [J].
Cornec, Divi ;
Devauchelle-Pensec, Valerie ;
Mariette, Xavier ;
Jousse-Joulin, Sandrine ;
Berthelot, Jean-Marie ;
Perdriger, Aleth ;
Puechal, Xavier ;
Le Guern, Veronique ;
Sibilia, Jean ;
Gottenberg, Jacques-Eric ;
Chiche, Laurent ;
Hachulla, Eric ;
Hatron, Pierre Yves ;
Goeb, Vincent ;
Hayem, Gilles ;
Morel, Jacques ;
Zarnitsky, Charles ;
Dubost, Jean Jacques ;
Saliou, Philippe ;
Pers, Jacques Olivier ;
Seror, Raphaele ;
Saraux, Alain .
ARTHRITIS CARE & RESEARCH, 2017, 69 (04) :528-535
[10]   High-Grade Salivary-Gland Involvement, Assessed by Histology or Ultrasonography, Is Associated with a Poor Response to a Single Rituximab Course in Primary Sjogren's Syndrome: Data from the TEARS Randomized Trial [J].
Cornec, Divi ;
Jousse-Joulin, Sandrine ;
Costa, Sebastian ;
Marhadour, Thierry ;
Marcorelles, Pascale ;
Berthelot, Jean-Marie ;
Hachulla, Eric ;
Hatron, Pierre-Yves ;
Goeb, Vincent ;
Vittecoq, Olivier ;
Nowak, Emmanuel ;
Pers, Jacques-Olivier ;
Devauchelle-Pensec, Valerie ;
Saraux, Alain .
PLOS ONE, 2016, 11 (09)